Esperion Therapeutics   Report issue

Contributed to NME For profit Phase 2 Phase 4
Founded: Ann Arbor MI United States (2008)

Organization Overview

First Clinical Trial
2010
NCT01105598
First Marketed Drug
2020
bempedoic acid (NEXLETOL)
First NDA Approval
2020
bempedoic acid (NEXLETOL)
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Esperion Therapeutics | Esperion Therapeutics, Inc. | ESPERION THERAPS INC

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atherosclerosis (Phase 3)

Cardiovascular Diseases (Phase 3)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Dyslipidemias (Phase 2)

Hypercholesterolemia (Phase 3)

Hyperlipidemias (Phase 3)

Hyperlipoproteinemias (Phase 3)

Hypertension (Phase 2)

Hypertriglyceridemia (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 24
  • # of Trial APIs: 7